220 related articles for article (PubMed ID: 27775713)
1. Small-molecule factor D inhibitors targeting the alternative complement pathway.
Maibaum J; Liao SM; Vulpetti A; Ostermann N; Randl S; Rüdisser S; Lorthiois E; Erbel P; Kinzel B; Kolb FA; Barbieri S; Wagner J; Durand C; Fettis K; Dussauge S; Hughes N; Delgado O; Hommel U; Gould T; Mac Sweeney A; Gerhartz B; Cumin F; Flohr S; Schubart A; Jaffee B; Harrison R; Risitano AM; Eder J; Anderson K
Nat Chem Biol; 2016 Dec; 12(12):1105-1110. PubMed ID: 27775713
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Lorthiois E; Anderson K; Vulpetti A; Rogel O; Cumin F; Ostermann N; Steinbacher S; Mac Sweeney A; Delgado O; Liao SM; Randl S; Rüdisser S; Dussauge S; Fettis K; Kieffer L; de Erkenez A; Yang L; Hartwieg C; Argikar UA; La Bonte LR; Newton R; Kansara V; Flohr S; Hommel U; Jaffee B; Maibaum J
J Med Chem; 2017 Jul; 60(13):5717-5735. PubMed ID: 28621538
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Karki RG; Powers J; Mainolfi N; Anderson K; Belanger DB; Liu D; Ji N; Jendza K; Gelin CF; Mac Sweeney A; Solovay C; Delgado O; Crowley M; Liao SM; Argikar UA; Flohr S; La Bonte LR; Lorthiois EL; Vulpetti A; Brown A; Long D; Prentiss M; Gradoux N; de Erkenez A; Cumin F; Adams C; Jaffee B; Mogi M
J Med Chem; 2019 May; 62(9):4656-4668. PubMed ID: 30995036
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Schubart A; Anderson K; Mainolfi N; Sellner H; Ehara T; Adams CM; Mac Sweeney A; Liao SM; Crowley M; Littlewood-Evans A; Sarret S; Wieczorek G; Perrot L; Dubost V; Flandre T; Zhang Y; Smith RJH; Risitano AM; Karki RG; Zhang C; Valeur E; Sirockin F; Gerhartz B; Erbel P; Hughes N; Smith TM; Cumin F; Argikar UA; Haraldsson B; Mogi M; Sedrani R; Wiesmann C; Jaffee B; Maibaum J; Flohr S; Harrison R; Eder J
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7926-7931. PubMed ID: 30926668
[TBL] [Abstract][Full Text] [Related]
6. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.
Dobó J; Kocsis A; Gál P
Front Immunol; 2018; 9():1851. PubMed ID: 30135690
[TBL] [Abstract][Full Text] [Related]
7. Complement Factor D protects mice from ethanol-induced inflammation and liver injury.
McCullough RL; McMullen MR; Sheehan MM; Poulsen KL; Roychowdhury S; Chiang DJ; Pritchard MT; Caballeria J; Nagy LE
Am J Physiol Gastrointest Liver Physiol; 2018 Jul; 315(1):G66-G79. PubMed ID: 29597356
[TBL] [Abstract][Full Text] [Related]
8. Induction of Ocular Complement Activation by Inflammatory Stimuli and Intraocular Inhibition of Complement Factor D in Animal Models.
Crowley MA; Delgado O; Will-Orrego A; Buchanan NM; Anderson K; Jaffee BD; Dryja TP; Liao SM
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):940-951. PubMed ID: 29450541
[TBL] [Abstract][Full Text] [Related]
9. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
10. Factor J, an inhibitor of the classical and alternative complement pathway, does not inhibit esterolysis by factor D.
González-Rubio C; González-Muñiz R; Jiménez-Clavero MA; Fontán G; López-Trascasa M
Biochim Biophys Acta; 1996 Jul; 1295(2):174-8. PubMed ID: 8695643
[TBL] [Abstract][Full Text] [Related]
11. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of alternative pathway factor D by factor B-related synthetic hexapeptides.
Lesavre P; Gaillard MH; Halbwachs-Mecarelli L
Eur J Immunol; 1982 Mar; 12(3):252-4. PubMed ID: 6920299
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular weight inhibitors of the alternative complement pathway.
Schubart A; Flohr S; Junt T; Eder J
Immunol Rev; 2023 Jan; 313(1):339-357. PubMed ID: 36217774
[TBL] [Abstract][Full Text] [Related]
14. Complement factor D homolog involved in the alternative complement pathway of rock bream (Oplegnathus fasciatus): Molecular and functional characterization and immune responsive mRNA expression analysis.
Godahewa GI; Perera NC; Bathige SD; Nam BH; Noh JK; Lee J
Fish Shellfish Immunol; 2016 Aug; 55():423-33. PubMed ID: 27311435
[TBL] [Abstract][Full Text] [Related]
15. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway.
Barratt J; Weitz I
Front Immunol; 2021; 12():712572. PubMed ID: 34566967
[TBL] [Abstract][Full Text] [Related]
16. Small molecule KDM4s inhibitors as anti-cancer agents.
Lin H; Li Q; Li Q; Zhu J; Gu K; Jiang X; Hu Q; Feng F; Qu W; Chen Y; Sun H
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):777-793. PubMed ID: 29651880
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471).
Wiles JA; Galvan MD; Podos SD; Geffner M; Huang M
Curr Med Chem; 2020; 27(25):4165-4180. PubMed ID: 31573880
[TBL] [Abstract][Full Text] [Related]
18. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.
Banda NK; Wood AK; Takahashi K; Levitt B; Rudd PM; Royle L; Abrahams JL; Stahl GL; Holers VM; Arend WP
Arthritis Rheum; 2008 Oct; 58(10):3081-9. PubMed ID: 18821684
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
[TBL] [Abstract][Full Text] [Related]
20. Age-related macular degeneration: a complementopathy?
Kijlstra A; Berendschot TT
Ophthalmic Res; 2015; 54(2):64-73. PubMed ID: 26159686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
